Battling low expectations and goliath rivals, Regeneron/Sanofi add positive Libtayo data in pursuit of blockbuster status
Latecomers Regeneron and Sanofi continue to claw their way forward in the tough PD-(L)1 market. Researchers for the checkpoint allies offered a positive pivotal snapshot of their PD-1 Libtayo early Tuesday, which could provide another boost in an oncology market dominated by Merck’s Keytruda and Bristol Myers’ Opdivo.
The research team journeyed out into a patient population with no approved therapy: basal cell carcinoma in patients whose disease had advanced beyond the reach of a Hedgehog pathway inhibitor — meaning Erivedge and Odomzo. Right now, that’s the end of the line in the treatment paradigm.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.